Among the 11 genes of the PIK3CA/AKT/mTOR pathway, PIK3CA mutations were highly enriched in the metastatic IBC group (38.8% vs. 13.8%, p = 0.0009). Here, PIK3CA is linked to inflammatory breast carcinoma.